NAVINFLUOR Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,045 Cr
verified against source
Revenue YoY
44%
reported change
EBITDA
₹357 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Navin Fluorine delivered an exceptional Q1 FY27 with consolidated revenue of Rs 1,045 crore (+44% YoY), EBITDA of Rs 357 crore (+73% YoY), and PAT of Rs 243 crore (+108% YoY). EBITDA margin expanded 566bps to 34.2%. All three verticals performed strongly: HPP (Rs 540 crore, +33%) benefited from volume growth and improved realizations in a constructive HFC pricing environment; Specialty Chemicals (Rs 325 crore, +48%) sustained momentum with good order visibility across existing and new molecules; CDMO (Rs 180 crore, +82%) deepened its European partnership with an additional molecule MSA. Management announced strategic capex including Rs 90 crore for advanced materials adoption capacity (Q2 FY28) and Rs 125 crore for CDMO Phase 2 CGMP (Q4 FY27). Key initiatives include the DRDO partnership for indigenous specialty materials and the Kimos liquid cooling project (Q2 FY27 completion). Looking ahead, medium-term margin guidance of 32-33% ±1% reflects confidence in operating leverage from upcoming capacities. Risk factors include specialty chemical pricing pressure in LatAm and raw material inflation impacting gross margins, though management indicated intent to pass through where pricing power exists.
Colored figures show movement against the previous available record.
Guidance to track
- Management confirmed the $100M revenue target for FY27 remains on track, supported by deepening European partnership and expanded MSA for an additional molecule in the same supply chain.
- Additional HFC capacity equivalent to 15,000 metric tons of R32 remains on track for Q3 FY27 commissioning, providing operating leverage for the group.
- Rs 90 crore capex for adoption capacity targeting commercial scale qualification of 5 lab-approved products, funded through internal accruals.
- Rs 125 crore Phase 2 CGMP capex expected to be operational by Q4 FY27, supported by growing demand from European CDMO partner, part of Rs 288 crore board-approved program.
Risks flagged
- Management acknowledged that pricing pressure continues particularly in the Latam market which is already well supplied. While volume growth is recovering, this creates uncertainty on margin trajectory for the segment.
- Gross margins contracted ~100bps between Q4 FY26 and Q1 FY27 due to rising raw material costs in an environment of global supply chain tensions. Management noted lag effect in passing through price increases.
- An analyst question on a Phase 3 molecule readout that 'didn't come quite well' highlighted the binary risk inherent in the late-stage CDMO pipeline. Management responded by emphasizing portfolio diversification with multiple molecules in development.
- An analyst questioned the sequential margin drop despite higher HPP and CDMO contribution, pointing to potential mix or operational issues that management attributed to campaign-driven quarterly variation and AHF subsidiary transfer pricing dynamics.
Key quotes
- We are not looking at it like a deer who's gazing through headlights. The important part here is to understand that 32 the long-term demand environment remains constructive. We all know that over a decade the demand for 32 is going to double while the supply kotadriven supply is going to shrink to half.
- The 90 crores that we are spending is sufficiently risk-managed because there are five products that have already been lab approved. This project while it's an adoption project is also going to self earn for itself and will pay back the money faster. Now this vertical is also going to be highly accreting to our margins.
- Numbers tell you only half the story. Q1 of last year, HF prices were very high. Today as we are speaking in a heightening global war tensions with supply chain risk, the cost of raw materials increasing etc. that profile will change. We constantly look for making sure that the price increase or inflation that we are seeing on the RM side is being passed on to the products wherever we have the pricing power.
Research modules